论文部分内容阅读
目的:观察全反式维甲酸(ATRA)联合三氧化二砷(ATO)双诱导与ATRA单诱导、ATO单诱导治疗急性早幼粒细胞白血病(APL)的临床疗效。方法:观察比较双诱导组(23例)、ATRA组(21例)和ATO组(20例)治疗APL的完全缓解(CR)率、早期病死率和不良反应发生情况。结果:双诱导组、ATRA组和ATO组的CR率分别为91.4%、81.0%和85.0%,早期病死率分别为4.3%、9.5%和5.0%,三组CR率及早期病死率无统计学差异(P>0.05)。双诱导组患者治疗期间肝功能异常较为明显。结论:ATRA+ATO双诱导方案治疗APL与ATRA或ATO单诱导方案相比,同样具有可靠的临床疗效,CR率提高,用药至缓解时间相对较短,早期病死率也较低。
Objective: To observe the clinical efficacy of ATRA combined with ATO dual induction and ATRA single induction and ATO single induction treatment of acute promyelocytic leukemia (APL). Methods: The complete remission (CR) rate, early mortality and adverse reactions of APL were observed and compared in double induction group (23 cases), ATRA group (21 cases) and ATO group (20 cases). Results: The CR rates of double induction group, ATRA group and ATO group were 91.4%, 81.0% and 85.0% respectively, and the early mortality rates were 4.3%, 9.5% and 5.0% respectively. There was no statistical difference in CR rate and early mortality Difference (P> 0.05). Double induction group patients with liver dysfunction during treatment more obvious. Conclusion: ATRA + ATO dual induction of APL and ATRA or ATO single induction program compared with the same reliable clinical efficacy, CR rate increased, medication to the remission time is relatively short, early mortality is also low.